No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 15 of the 38 quarters in the window, leaving 23 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 4.7x · 10Y median 32.2x · 13th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:16.052Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cue Biopharma, Inc. (CUE) stock was $24.58 as of Oct 6, 2026, 10:04 AM EDT, up 0.90% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +11.3% · 3-year avg -28.6%/yr · 5-year avg -42.4%/yr
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies.
Biotechnology · Boston, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-2.24
Revenue Est.
$1.03M
Last Quarter Results
EPS
$-24.14
vs Estimate
$-1.69
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CUE | $178.56M | $24.58 | +0.90% | +11.33% | -42.42% | N/A | N/A |
| 2CNTN | $180.85M | $2.35 | +0.64% | -19.85% | N/A | N/A | vs CUE |
| 3CMPX | $175.87M | $0.98 | +1.67% | -73.87% | -22.79% | N/A | vs CUE |
| 4DERM | $181.64M | $6.60 | -1.35% | -8.69% | N/A | N/A | vs CUE |
| 5DTIL | $172.92M | $6.26 | -0.71% | +15.91% | -54.84% | N/A | vs CUE |
| 6MDWD | $172.74M | $13.45 | -0.47% | -21.32% | -9.04% | -12.86% | vs CUE |
forward FY estimate
N/A
$7.88M
vs Estimate
$3.00M
Consensus Rating
Based on 3 analysts
Average Price Target
$88.00
+258.0% upside
Low
$66.00
Current
$24.58
High
$115.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.24 | $-2.24 | $-2.24 | 2 |
| Quarter ending Dec 2026 | $-1.76 | $-1.76 | $-1.76 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-35.22 | $-25.01 | $-17.60 | 2 |
| FY 2027 | $-10.48 | $-7.44 | $-5.24 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.03M | $1.03M | $1.03M | 3 |
| Quarter ending Dec 2026 | $1.00M | $1.00M | $1.00M | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $12.06M | $15.62M | $20.53M | 2 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $6.68M |
| $8.65M |
| $11.37M |
| 2 |
